- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03578133
Causes of Pneumonia in Yangon
A Cross-sectional Study Investigating the Causes of Pneumonia in Two Community Clinics in Two Yangon Townships, Myanmar
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Melioidosis is caused by Burkholderia pseudomallei, a Gram-negative saprophytic environmental bacterium that is an important emerging tropical infection. There are an estimated 165,000 cases and 89,000 deaths world-wide each year. Eighty-four percent of cases are in SE Asia where mortality is 40%; far exceeding most recognised neglected tropical diseases. Pneumonia, secondary to either inhalation of B.pseudomallei or to bacteraemic spread to the lung is the commonest presentation (51%). Annually the highest burden (75%) of infection occurs in the rainy season in (75% in Thailand). Up to 80% patients have at least one recognised risk factor for melioidosis including; diabetes, alcohol-dependence, glucocorticoid therapy, chronic obstructive pulmonary disease (COPD), chronic renal disease and cancer. COPD and diabetes mellitus are amongst the top ten causes of death in Myanmar (2018). Patients with HIV have not been shown to have greater risk of B. pseudomallei than immunocompetent patients.
Melioidosis was discovered in Myanmar in 1911 by British pathologist Alfred Whitmore and his assistant CS Krishnaswami. Yet since 1949 there have been few published cases. Under-reporting is partly due to difficulty in diagnosing melioidosis. Clinical and radiological findings are indistinguishable from tuberculosis. Laboratory diagnosis is challenging, lack of facilities, expertise and awareness of B.pseudomallei results in missed diagnostic opportunities.
Culture is the gold-standard diagnostic method but requires appropriate facilities and expertise which are not readily available in many developing countries like Myanmar. A rapid diagnostic (RDT) test has been developed for low resource settings that has been evaluated in Laos and India. The InBios® Active Melioidosis DetectTM-Lateral Flow Assay (AMD-LFA) detects B.pseudomallei 6-deoxyheptan capsular polysaccharide antigen. Shaw et al demonstrated sensitivity 85.71% (CI:74.61% to 93.25%) and specificity 93.62% (CI:88.23% to 97.04%), with positive predictive value of 85.71% (CI: 75.98% to 91.92%) compared to culture. We propose to evaluate this test for the diagnosis of melioidosis pneumonia in Myanmar.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Yangon, Myanmar
- Medical Action Myanmar Clinics
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- >18 years old
- Reported fever or axillary temperature > 37.5 °C
- Productive cough
- Written informed consent
Exclusion Criteria:
1. Inability to provide a sputum specimen
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with a positive B.pseudomallei culture result
Time Frame: January 2019
|
Number of patients with a positive sputum culture for B.pseudomallei expressed as a proportion of all patients
|
January 2019
|
1) Sensitivity, specificity, positive predictive value, negative predictive value of the RDT compared to culture
Time Frame: January 2019
|
Using culture as the gold-standard the performance of the lateral flow assay will be assessed
|
January 2019
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients diagnosed with tuberculosis (TB) including multidrug resistant TB
Time Frame: January 2019
|
Proportion of enrolled participants with a positive GeneXpert MTB/RIF test on sputum
|
January 2019
|
Proportion of patients diagnosed with Influenza A/B
Time Frame: March 2019
|
Proportion of enrolled participants with a positive Xpert Flu test on nasopharyngeal swab
|
March 2019
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Elizabeth A Ashley, Dr, Myanmar Oxford Clinical Research Unit
- Study Director: Clare Warrell, Dr, Myanmar Oxford Clinical Research Unit and Medical Action Myanmar
- Study Director: David Dance, Prof, Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit
- Study Director: Mo Mo Win, Dr, Department of Medical Research, Myanmar
- Study Director: Alistair McLean, Dr, Myanmar Oxford Clinical Research Unit
Publications and helpful links
General Publications
- Limmathurotsakul D, Golding N, Dance DA, Messina JP, Pigott DM, Moyes CL, Rolim DB, Bertherat E, Day NP, Peacock SJ, Hay SI. Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis. Nat Microbiol. 2016 Jan 11;1:15008. doi: 10.1038/nmicrobiol.2015.8.
- Houghton RL, Reed DE, Hubbard MA, Dillon MJ, Chen H, Currie BJ, Mayo M, Sarovich DS, Theobald V, Limmathurotsakul D, Wongsuvan G, Chantratita N, Peacock SJ, Hoffmaster AR, Duval B, Brett PJ, Burtnick MN, Aucoin DP. Development of a prototype lateral flow immunoassay (LFI) for the rapid diagnosis of melioidosis. PLoS Negl Trop Dis. 2014 Mar 20;8(3):e2727. doi: 10.1371/journal.pntd.0002727. eCollection 2014 Mar.
- Chierakul W, Wuthiekanun V, Chaowagul W, Amornchai P, Cheng AC, White NJ, Day NP, Peacock SJ. Short report: disease severity and outcome of melioidosis in HIV coinfected individuals. Am J Trop Med Hyg. 2005 Dec;73(6):1165-6.
- Shaw T, Tellapragada C, Ke V, AuCoin DP, Mukhopadhyay C. Performance evaluation of Active Melioidosis Detect-Lateral Flow Assay (AMD-LFA) for diagnosis of melioidosis in endemic settings with limited resources. PLoS One. 2018 Mar 26;13(3):e0194595. doi: 10.1371/journal.pone.0194595. eCollection 2018.
- Woods KL, Boutthasavong L, NicFhogartaigh C, Lee SJ, Davong V, AuCoin DP, Dance DAB. Evaluation of a Rapid Diagnostic Test for Detection of Burkholderia pseudomallei in the Lao People's Democratic Republic. J Clin Microbiol. 2018 Jun 25;56(7):e02002-17. doi: 10.1128/JCM.02002-17. Print 2018 Jul.
- Wiersinga WJ, Currie BJ, Peacock SJ. Melioidosis. N Engl J Med. 2012 Sep 13;367(11):1035-44. doi: 10.1056/NEJMra1204699. No abstract available.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OXTREC 19-18
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melioidosis Pneumonia
-
Khon Kaen UniversityCompleted
-
University of OxfordWellcome Trust; Mahidol UniversityUnknown
-
AN2 Therapeutics, IncMahidol Oxford Tropical Medicine Research UnitRecruitingMelioidosisThailand, Lao People's Democratic Republic
-
Arrevus Inc.Arnasi GroupCompleted
-
Khon Kaen UniversityUnknownMelioidosis | Head and Neck InfectionThailand
-
Foundation for Innovative New Diagnostics, SwitzerlandCompletedDiagnoses Disease | Acute Febrile Illness | MelioidosisAustralia
-
Institute of Tropical Medicine, BelgiumSRI International; Sihanouk Hospital Center of HOPECompletedSystemic Inflammatory Response Syndrome | Melioidosis | Suspected or Confirmed Bloodstream InfectionsCambodia
-
King Edward Memorial HospitalCompletedNosocomial Pneumonia | Healthcare-Associated Pneumonia | Aspiration Pneumonia | Ventilator-Associated PneumoniaIndia